Drug Type Small molecule drug |
Synonyms Sacubatril/allisartan medoxomil, 沙库巴曲阿利沙坦钙, AHU-377/EXP3174 + [2] |
Target |
Action antagonists, inhibitors |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), enkephalinase inhibitors(Neprilysin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC24H29NO5 |
InChIKeyPYNXFZCZUAOOQC-UTKZUKDTSA-N |
CAS Registry149709-62-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | NDA/BLA | China | 07 Jul 2023 | |
Heart failure with reduced ejection fraction | Phase 3 | China | 12 Apr 2022 | |
Renal Insufficiency | Phase 1 | China | 07 Sep 2022 | |
Hepatic Insufficiency | Phase 1 | China | 08 Jun 2022 | |
Chronic heart failure | Phase 1 | China | 26 Dec 2018 |